Using the abYsis database for drug discovery
Posted 30th April 2021 by Nicholas Noakes
Professor Andrew Martin, UCL, speaking at the 4th Global Pharma R&D AI, Data Science and Informatics Summit, described using the abYsis database and workbench for drug discovery. He showed how it is possible to explore an annotate antibody sequence and structure, including comparisons with observed residue distributions. The database can also aid with humanization by making sequences more human and library design.
Ireland and the Future of Biopharmaceutical Manufacturing
Posted 16th December 2019 by Liv Sewell
Ahead of the 3rd Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress in Dublin, we consider how Ireland is uniquely positioned to play a significant role in the next generation of biopharmaceutical manufacturing and delivery of life changing medicines.
Diversity and Inclusion in a scientific context
Posted 8th February 2019 by Joshua Sewell
You have probably already heard of diversity and inclusion, but isn’t this just another management term? No, not this time! I hope I can convince you that there is real magic in inclusion and embracing diversity. I will introduce you to the world of diversity and inclusion, what it looks like in your daily work routine, and how it can help you and your team. I will also provide you with a few tools and ideas on how to improve inclusion within your team.
Round-Up of Top Biologics News
Posted 18th July 2018 by Jane Williams
With new discoveries and developments in Asthma, Diabetes and Cancer, there has been some interesting news to catch up on this month. Take a look at the list below to find out more:
Biologics Congress Europe – Slide release
Posted 6th June 2018 by Jane Williams
Presented at the 4th Biologics & Biosimilars Congress, these free slides are now available to download and share with your colleagues.
Antibody Drug Conjugates: Bioanalytical Assay Challenges and Strategies
Posted 8th January 2018 by Jane Williams
Antibody-drug conjugates (ADCs) combine the high specificity of a monoclonal antibody (mAb) for a target antigen with the highly potent cytotoxic activity of small-molecule drugs. Although the concept behind ADCs is relatively simple, the successful design and development of ADCs is a complex task. Similar to other biotherapeutics, the understanding of Pharmacokinetics (PK), Pharmacodynamics (PD), and Absorption, Distribution, Metabolism, and Excretion (ADME) properties of ADCs is critical for their successful development.
A Vision for the Second Green Revolution
Posted 8th December 2017 by Jane Williams
There is a Second Green Revolution underway that is harnessing precision agriculture, no-till farming practices, biological, rather than chemical crop inputs and other new, innovative tools that improve soil health and water quality.
Presentation Slide Release: Biologics Discovery and Development
Posted 9th October 2017 by Jane Williams
Presented at the 3rd Biologics and Biosimilars Congress, these 3 sets of slides are available to download and share with your colleagues.
